General Information of the Drug (ID: M6APDG04218)
Name
Telisotuzumab vedotin
Synonyms
ABBV-399
    Click to Show/Hide
Status
Phase 2
TTD Drug ID
D42TUS
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Proto-oncogene c-Met (MET)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
Response Summary Proto-oncogene c-Met (MET) is a therapeutic target for Telisotuzumab vedotin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Telisotuzumab vedotin through regulating the expression of Proto-oncogene c-Met (MET). [1], [2]
References
Ref 1 RNA m(6) A methylation regulates uveal melanoma cell proliferation, migration, and invasion by targeting c-Met. J Cell Physiol. 2020 Oct;235(10):7107-7119. doi: 10.1002/jcp.29608. Epub 2020 Feb 4.
Ref 2 Clinical pipeline report, company report or official report of Apollomics.